race oncology raises $29.7m to fund development of lead anti-cancer drug zantrene
Published 2 years ago • 2.4K plays • Length 22:42Download video MP4
Download video MP3
Similar videos
-
6:42
race oncology looks to accelerate clinical development of bisantrene
-
6:42
race oncology (asx: rac) reveals breakthrough chemotherapy heart protection discovery for zantrene®
-
0:49
race oncology reports bisantrene shows potent anti-cancer activity
-
3:01
the chemo tox man - learn chemotherapy side effects in 3 minutes
-
3:38
cancer treatment: imrt (radiation therapy)
-
4:39
mechanism of cisplatin - chemotherapy
-
14:22
pharmacology - chemotherapy agents (moa, alkalating, antimetabolites, topoisomerase, antimitotic )
-
0:36
race trials new zantrene drug for extramedullary acute myeloid leukaemia (emd aml) – animation
-
27:35
race oncology (asx: rac) – breakthrough cancer treatment discovery
-
9:44
production of plant-derived anti-cancer drug- lead camptothecin via microbial fermentation route
-
6:06
race oncology brings in $29.7 million war chest to "get to the clinic"
-
20:31
race oncology (asx: rac) – zantrene’s role as an fto inhibitor to cure cancer globally
-
6:45
how to remember classification of anticancer drugs??
-
5:32
pharmacology - cancer oncology drugs nursing rn pn full video (made easy)
-
3:47
anti-cancer drugs side effects (chemo toxicities) - visual mnemonic
-
15:38
pharmacology- anti cancer drugs (cell cycle specific and cell cycle non specific- made easy!
-
2:56
roche in oncology
-
32:00
race oncology (asx: rac) day 2 of the ird invest 2021 conference.
-
5:00
race oncology secures governance approval for open-label zantrene trial
-
30:50
mst access australian micro & small caps conference 2021 - race oncology limited
-
0:31
lamea oncology/anti-cancer drugs market trends & growth, forecast - 2022